Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants...
Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan
read more
Search Results
Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring
A large majority of creditors and shareholders have voted in favor of the draft safeguard plan This plan includes a 70% reduction in debt,...
Mauna Kea Technologies Announces 2025 Half-Year Results
32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S....
Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan
Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan...
Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion
Paris, Boston and Sydney, September 18, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today...
Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround
Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties...
Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio
New letter published by the AFS highlights Cellvizio’s superiority to conventional tools for detecting pre-cancerous tissue and dysplasia ...
Mauna Kea Technologies Reports First Half 2025 Revenue
On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard...
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth...
Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S.
14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the...
Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio
Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The...
Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure
Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire...